- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03966521
The British Society of Endovascular Therapy ConformabLe EndoVascular Aneurysm Repair Registry (BSET-CLEVAR)
The British Society of Endovascular Therapy ConformabLe EndoVascular Aneurysm Repair (BSET-CLEVAR) Registry
The purpose of the BSET-CLEVAR Registry is to collect device-specific performance outcomes of the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System (EXCC device) in routine clinical treatment of patients with abdominal aortic aneurysm in the UK.
The novel EXCC device is an evolution of an established device allowing active shaping to conform to the specific patient aortic neck anatomy, with more accurate deployment, potentially greater neck coverage and better long term fixation/sealing. This may translate to improved effectiveness of this device over time, reducing the need for any further procedures. The primary aim of this study is to assess the degree of neck coverage by the EXCC device.
The British Society of Endovascular Therapy (BSET) has received funds from the stent manufacturer (W.L. Gore & Associates, Inc.) to conduct this study. BSET and the Sponsor (Imperial College London) have full responsibility for the design, conduct, analysis and reporting of the study.
Study Overview
Status
Conditions
Detailed Description
An abdominal aortic aneurysm (AAA) is a 'bulge' caused by weakness of the wall of the aorta (main blood vessel) in the section that travels down through the abdomen. An AAA can grow to a large size over time and it may burst (rupture), causing life-threatening internal bleeding. The standard method to prevent the AAA from bursting is to re-line the aorta with an artificial piece of rigid tubing called a stent that has been covered with material. This is inserted through the blood vessels from the artery in the groin to stop the aneurysm from expanding and restore normal diameter of the aorta. This is commonly known as a 'keyhole'or minimally invasive approach called endovascular aneurysm repair (EVAR).
There have been many advances in stent-graft technology to improve the accuracy and effectiveness of the EVAR procedure. A new design of an existing stent-graft that is currently being used in patients in many hospitals is the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL (also known as EXCC Device). This new device allows the operator to shape the upper end of the device so that it may be placed into the aorta more accurately, conforming to the shape of the aorta, potentially improving the fixation and long-term sealing of the aneurysm, which may translate to a reduction in the need for further procedures.
This study is a prospective, multi-centre observational cohort registry of patients undergoing routine clinical treatment of AAA by the EXCC device. Recruitment will take place in 13 experienced UK centres with extensive EVAR experience. Up to 150 participants will be recruited in 30 months and followed-up to 1 year (participants will not undergo any procedure that is not part of their routine clinical care). Clinical data and device specific outcomes, including complications and re-interventions will be prospectively collected. In addition, the BSET-CLEVAR Registry Core Lab will evaluate both the pre-operative CT scan and the post-operative CT scan (obtained between 4 weeks and 3-months following EVAR), to assess the primary outcome of the study (endograft positioning accuracy and aortic neck coverage expressed as percentage of the total aortic neck assessed). Study outcomes will also include detailed analysis of pathological and anatomical features of the aneurysm and the EXCC device, which will be used for reporting the effectiveness of the graft. A detailed statistical analysis plan will be written prior to the final analysis.
The Study Co-ordinating Centre based at Imperial College London is responsible for the overall coordination of the Study, including monitoring of the overall study progress and review of study data accuracy (which, if necessary, may be checked by auditing the source data).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Aberdeen, United Kingdom, AB25 2ZN
- NHS Grampian
-
Bedford, United Kingdom, MK42 9DJ
- Bedford Hospital NHS Trust
-
Bournemouth, United Kingdom, BH7 7DW
- University Hospitals Dorset NHS Foundation Trust
-
Cambridge, United Kingdom, CB2 0QQ
- Cambridge University Hospitals NHS Foundation Trust
-
Cheltenham, United Kingdom, GL53 7AN
- Gloucestershire Hospitals NHS Foundation Trust
-
Dundee, United Kingdom
- NHS Tayside
-
Leeds, United Kingdom, LS1 3EX
- Leeds Teaching Hospitals NHS Trust
-
Liverpool, United Kingdom
- Liverpool University Hospitals NHS Foundation Trust
-
London, United Kingdom, SE1 7EH
- Guy's and St Thomas' NHS Foundation Trust
-
Norwich, United Kingdom
- Norfolk and Norwich University Hospitals NHS Foundation Trust
-
-
East Yorkshire
-
Hull, East Yorkshire, United Kingdom, HU3 2JZ
- Hull & East Yorkshire Hospitals NHS Trust (Hull Royal Infirmary)
-
-
Surrey
-
Frimley, Surrey, United Kingdom, GU16 7UJ
- Frimley Health NHS Foundation Trust
-
-
Westminster
-
London, Westminster, United Kingdom, W2 1NY
- Imperial College Healthcare NHS Trust (St Mary's Hospital)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
The patient is / has:
- Age 55 or more at the time of informed consent signature.
- Non-ruptured infra-renal AAA that requires treatment, and in the opinion of the Investigator, whose anatomy is adequate to receive or has already received the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System (EXCC device).
- A signed and dated Informed Consent Form signed by the patient either before or within 30 days of EXCC device implantation
Exclusion Criteria:
The patient is / has:
- Previous infra-renal aortic surgery
- Been treated in another aortic or thoracic medical device study within 1 year of study enrollment.
- Active infection
- Penetrating aortic ulcer or dissection or intramural haematoma in the treated segment
- Any clinically significant medical condition, which in the opinion of the investigator, may interfere with the study results or reduce life expectancy to <2 years
- In the opinion of the investigator unable or unwilling to comply with the requirements of the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endograft positioning accuracy and aortic neck coverage expressed as percentage of the total aortic neck assessed by CT images
Time Frame: between 4 weeks and 3 months following EVAR
|
The median aortic neck surface area utilized will be calculated from pre- and post-operative CT images, which will be obtained between 4 weeks and 3 months following primary EVAR procedure (timing depends on local EVAR surveillance policy)
|
between 4 weeks and 3 months following EVAR
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical success defined as successful access and deployment of all required EXCC Device components
Time Frame: At the end of the primary procedure
|
(Yes/No) - Success defined as no type I/III endoleak, no conversion to open repair & patient leaving theatre alive; to be assessed by the operating clinician on completion of EVAR
|
At the end of the primary procedure
|
In-hospital mortality
Time Frame: During hospital admission for the primary EVAR procedure, to be reported for up to 12 months following the primary procedure
|
Death occurring during hospital stay for EVAR
|
During hospital admission for the primary EVAR procedure, to be reported for up to 12 months following the primary procedure
|
Adjunct (supplementary) procedures received by the patient to resolve Type 1 endoleak on completion of EVAR
Time Frame: At the end of the primary EVAR procedure
|
Further steps (procedures) required to deal with type 1 endoleak (a failure of the first section of the stent-graft as it is fixed in the aorta below the renal arteries)
|
At the end of the primary EVAR procedure
|
Freedom from Type 1 or 3 endoleak
Time Frame: At the end of the primary procedure; at first follow-up (between 4 weeks and 3 months); at second follow-up (1 year)
|
No type 1 endoleak (a failure of the first section of the stent-graft as it is fixed in the aorta below the renal arteries) or Type 3 endoleak (a failure of sealing of the components of the stent-graft)
|
At the end of the primary procedure; at first follow-up (between 4 weeks and 3 months); at second follow-up (1 year)
|
One-year aneurysm-related re-intervention rate
Time Frame: One year after the primary procedure
|
Any further aneurysm-related procedures that occur within 12 months following EVAR
|
One year after the primary procedure
|
One-year aneurysm-related mortality
Time Frame: One year after the primary procedure
|
Vital status of the patient one year after undergoing EVAR
|
One year after the primary procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Colin D Bicknell, MB MD FRCS, Imperial College London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19SM5135
- IRAS Project ID: 260562 (Other Identifier: Health Research Authority)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abdominal Aortic Aneurysm Without Rupture
-
Rede Optimus Hospitalar SAShockwave Medical, Inc.Not yet recruitingThoracoabdominal Aortic Aneurysm, Without Mention of Rupture | Abdominal Aortic Aneurysm Without Rupture | Thoracic Aortic Aneurysm Without Rupture
-
Dr. Sabrina OverhagenActive, not recruitingThoracoabdominal Aortic Aneurysm, Without Mention of Rupture | Abdominal Aortic Aneurysm, Without Mention of RuptureGermany
-
Karolinska University HospitalEnrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
Karolinska University HospitalMedical University of Graz; St. Olavs HospitalCompletedAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Nano4Imaging GmbH; BrightfishRecruitingAbdominal Aortic Aneurysm Without RuptureNetherlands
-
Imperial College LondonW.L.Gore & Associates; MedtronicNot yet recruiting
-
Centre hospitalier de l'Université de Montréal...McGill University; University of Calgary; Eindhoven University of TechnologyRecruitingAbdominal Aortic Aneurysm Without RuptureCanada
-
EndologixActive, not recruitingAbdominal Aortic Aneurysm Without RuptureUnited States
-
Hospital Sao JoaoCompletedAbdominal Aortic Aneurysm Without RupturePortugal
-
Hangzhou Endonom Medtech Co., Ltd.UnknownJuxta Renal Abdominal Aortic Aneurysm Without RuptureChina